US Stock Alert: argenx Plunges on October 8 Due to Termination of Trials, Insufficient Efficacy, and Pipeline Setbacks
Bitget异动解读2026/10/08 12:30argenx October 8 Sharp Decline Interpretation
Keywords: trial termination, lack of efficacy, pipeline setback
1. On October 8, 2026, an interim analysis by the independent data monitoring committee found that the efgartigimod subcutaneous injection failed to meet its primary endpoint in the phase III UNITY trial for Sjögren’s syndrome, and the company therefore decided to terminate the trial; this outcome dampens expectations for expanding Vyvgart’s indication to this disease, although no new safety concerns were identified.
2. On October 8, 2026, although the FB102 phase II trial for celiac disease achieved its primary endpoint, the project remains in mid-stage development and is planned to advance to phase III, making it difficult to offset the impact of the UNITY trial termination on pipeline expectations in the short term.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
【US Stock Movement】Pacira BioSciences surges on October 8: Viatris acquisition and cash tender offer
Spot platinum surpasses $1,640 per ounce
Spot platinum has just surpassed the $1,640.00/oz mark, currently quoted at $1,639.75/oz, up 0.41% on the day. The main Nymex platinum futures contract is currently quoted at $1,648.0/oz, down 0.11% on the day.
AI rack upgrades enter the "system efficiency battle"! With the OCP Summit approaching, Jefferies decodes 1.6T scale-up, memory expansion, and high-voltage power supply.
According to Zhitong Finance APP, with the upcoming US earnings season, the Nasdaq's record highs and Marvell's management raising its growth target have both served as positive catalysts for upward revisions in profit forecasts throughout the global AI optical interconnect industry chain. On October 6, the Nasdaq Composite Index rose 0.45%, closing at a record high of 27,599.79 points. Marvell (MRVL.US), a leader in ASIC and AI data center optical interconnect chips, raised its fiscal year 2028 revenue target from $18 billion to $20 billion, an increase of approximately 11.1%. The company's stock price rose 5.8% on the day, reflecting the market's strong expectations for expanding demand for accelerated computing chips and CPUs, HBM/DRAM/NAND memory chips, and data center optical interconnect components for AI data centers.
Crypto prices
More
